Hologic CEO to Retire After Go-Private Deal

Steve MacMillan will step down upon completion of the company's acquisition by private equity firm.

Apr. 6, 2026 at 1:56pm

Hologic, a major medical technology company, has announced that its Chief Executive Officer Steve MacMillan will retire upon the close of the company's go-private transaction. MacMillan has led Hologic for over a decade, guiding the firm through significant growth and expansion.

Why it matters

The retirement of a long-serving CEO like MacMillan is a significant event for a public company, especially one undergoing a major ownership change. This transition will likely have implications for Hologic's strategic direction and operations as it shifts to private ownership.

The details

Under MacMillan's leadership, Hologic has become a leading provider of diagnostic and surgical products for women's health. The company has agreed to be acquired by a private equity firm, which will take Hologic private. MacMillan will step down upon the close of this transaction, ending his 13-year tenure as CEO.

  • Hologic announced the go-private deal on April 6, 2026.
  • MacMillan will retire upon the close of the acquisition, which is expected to occur later in 2026.

The players

Steve MacMillan

The outgoing Chief Executive Officer of Hologic, who has led the medical technology company for over a decade.

Hologic

A major medical technology company that provides diagnostic and surgical products, primarily focused on women's health.

Got photos? Submit your photos here. ›

What they’re saying

“It has been an honor to lead Hologic for the past 13 years and to work alongside our talented team to transform the company into a global leader in women's health.”

— Steve MacMillan, Chief Executive Officer, Hologic

What’s next

The go-private transaction is expected to close later in 2026, at which point Steve MacMillan will officially retire as Hologic's CEO.

The takeaway

The retirement of Hologic's long-serving CEO coincides with the company's transition to private ownership, signaling a new chapter for the medical technology firm as it looks to continue its growth and innovation under new leadership.